基于结构的设计的新型G蛋白结合受体TAAR1激动剂作为潜在的抗精神病药物候选药物
Zhenzhen Zhou1, Weifeng Zhang2, Fabao Zhao1
1Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, China.
Journal of medicinal chemistry
|February 28, 2024
概括
一种新的候选药物,6e·HCl,通过准微氨基关联受体1 (TAAR1) 途径,显示出治疗精神分裂症的希望. 它有效地改善了动物模型中的认知功能,而不会引起诸如催眠症之类的不良影响.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 目前的抗精神病药物不足以解决精神分裂症的认知缺陷,并引起显著的副作用.
- 微氨基关联受体1 (TAAR1) 是开发新型抗精神病药物的有希望的治疗标.
- TAAR1激动剂通过调节参与精神病的神经递质系统,提供了提高疗效和安全性的潜力.
研究的目的:
- 设计和合成用于精神分裂症治疗的新型TAAR1激动剂.
- 在临床前模型中研究化合物6e的作用机制和疗效.
- 评估6e·HCl作为潜在治疗剂的药理动力学和安全性.
主要方法:
- 针对激活口袋的TAAR1激动剂的基于结构的设计.
- 在体外评估TAAR1通路激活 (Gs/Gq信号传递).
- 在MK-801诱导的精神分裂症动物模型中对认知效应的体内评估.
- 对6e·HCl的药理动力学和安全性评估.
主要成果:
- 化合物6e表现出强大的TAAR1-Gs/Gq双通路激活,与现有候选物不同.
- 6e在动物模型中显著改善了类似精神分裂症的认知障碍,而没有诱导触觉.
- 6e·HCl表现出有利的药理动力学特性 (T1/2 = 2.31 h,F = 39%) 和良好的安全性.
结论:
- 6e代表了一种具有独特的双通道TAAR1激活配置文件的新化学实体.
- 6e·HCl显示出作为一种新型治疗候选药物,用于管理精神分裂症认知功能障碍的显著潜力.
- 这些发现支持6e·HCl用于精神分裂症治疗的进一步临床开发.
相关概念视频
Antipsychotic Drugs: Typical and Atypical Agents
198
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
198
Structure-Activity Relationships and Drug Design
718
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
718
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
G-protein Coupled Receptors
118.8K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
118.8K


